Infections associated with clozapine: a pharmacovigilance study using VigiBase ®
Discussion: Our study revealed a significant safety signal between clozapine use and infections, predominantly respiratory and gastrointestinal infections. The co-administration of clozapine with valproic acid or proton pump inhibitors may potentially contribute to an increased risk of infection. Further vigilance is warranted in clinical practice, and consideration of therapeutic drug monitoring of clozapine in cases involving concomitant use of these drugs or in the presence of infections may be beneficial. (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - October 2, 2023 Category: Drugs & Pharmacology Source Type: research
Keverprazan, a novel potassium-competitive acid blocker: single ascending dose safety, tolerability, pharmacokinetics, pharmacodynamics and food effect in healthy subjects
CONCLUSION: Keverprazan is tolerable, and provides significant stable and lasting inhibition efficacy of intragastric acidity at 20 mg.PMID:37666458 | DOI:10.1016/j.ejps.2023.106578 (Source: European Journal of Pharmaceutical Sciences)
Source: European Journal of Pharmaceutical Sciences - September 4, 2023 Category: Drugs & Pharmacology Authors: Sufeng Zhou Lijun Xie Chen Zhou Yuqing Zhao Lu Wang Sijia Ding Juan Chen Bei Zhu Mei Su Feng Shao Source Type: research
Keverprazan, a novel potassium-competitive acid blocker: single ascending dose safety, tolerability, pharmacokinetics, pharmacodynamics and food effect in healthy subjects
CONCLUSION: Keverprazan is tolerable, and provides significant stable and lasting inhibition efficacy of intragastric acidity at 20 mg.PMID:37666458 | DOI:10.1016/j.ejps.2023.106578 (Source: European Journal of Pharmaceutical Sciences)
Source: European Journal of Pharmaceutical Sciences - September 4, 2023 Category: Drugs & Pharmacology Authors: Sufeng Zhou Lijun Xie Chen Zhou Yuqing Zhao Lu Wang Sijia Ding Juan Chen Bei Zhu Mei Su Feng Shao Source Type: research
Molecular Insights into the Mechanism of Modulatory Effects of Proton Pump Inhibitors on P-glycoprotein Mediated Drug Transport of Palbociclib and Ribociclib
CONCLUSION: The experimental evidence presented highlights the fact that proton pump inhibitors have potential to inhibit P-glycoprotein, giving rise to drug interactions with palbociclib and ribociclib. Hence, monitoring is required while proton pump inhibitors and cyclin-dependent kinase inhibitors are being co-administered to avoid adverse events.PMID:37581514 | DOI:10.2174/1389200224666230815122312 (Source: Current Drug Metabolism)
Source: Current Drug Metabolism - August 15, 2023 Category: Drugs & Pharmacology Authors: Mrunal Pradeep Desai Prajakta Harish Patil Sai Krishna Anand Vullendula Sumit Birangal G Gautham Shenoy Mahadev Rao Swapnil Jayant Dengale Krishnamurthy Bhat Jagadish Puralae Channabasavaiah Source Type: research
Molecular Insights into the Mechanism of Modulatory Effects of Proton Pump Inhibitors on P-glycoprotein Mediated Drug Transport of Palbociclib and Ribociclib
CONCLUSION: The experimental evidence presented highlights the fact that proton pump inhibitors have potential to inhibit P-glycoprotein, giving rise to drug interactions with palbociclib and ribociclib. Hence, monitoring is required while proton pump inhibitors and cyclin-dependent kinase inhibitors are being co-administered to avoid adverse events.PMID:37581514 | DOI:10.2174/1389200224666230815122312 (Source: Current Drug Metabolism)
Source: Current Drug Metabolism - August 15, 2023 Category: Drugs & Pharmacology Authors: Mrunal Pradeep Desai Prajakta Harish Patil Sai Krishna Anand Vullendula Sumit Birangal G Gautham Shenoy Mahadev Rao Swapnil Jayant Dengale Krishnamurthy Bhat Jagadish Puralae Channabasavaiah Source Type: research
Molecular Insights into the Mechanism of Modulatory Effects of Proton Pump Inhibitors on P-glycoprotein Mediated Drug Transport of Palbociclib and Ribociclib
CONCLUSION: The experimental evidence presented highlights the fact that proton pump inhibitors have potential to inhibit P-glycoprotein, giving rise to drug interactions with palbociclib and ribociclib. Hence, monitoring is required while proton pump inhibitors and cyclin-dependent kinase inhibitors are being co-administered to avoid adverse events.PMID:37581514 | DOI:10.2174/1389200224666230815122312 (Source: Current Drug Metabolism)
Source: Current Drug Metabolism - August 15, 2023 Category: Drugs & Pharmacology Authors: Mrunal Pradeep Desai Prajakta Harish Patil Sai Krishna Anand Vullendula Sumit Birangal G Gautham Shenoy Mahadev Rao Swapnil Jayant Dengale Krishnamurthy Bhat Jagadish Puralae Channabasavaiah Source Type: research
The efficacy and safety of vonoprazan –amoxicillin dual therapy in eradicating Helicobacter pylori: a systematic review and meta-analysis
ConclusionCompared with PPI-based triple therapy, VA dual therapy showed a better therapeutic effect, safety and patient compliance rate for eradicatingH. pylori, which should be used as a novel curative strategy in the future. (Source: European Journal of Medical Research)
Source: European Journal of Medical Research - August 7, 2023 Category: Research Source Type: research
CYP2C19 and CYP3A4 activity is associated with survival in ticagrelor-treated patients after ST-elevation myocardial infarction
Background and Aims: We assessed the effect of CYP450 activity assessed by lansoprazole metabolism on 7 year-survival of 89 patients with STEMI treated by PCI together with prasugrel (n = 46) and ticagrelor (n = 49). (Source: Atherosclerosis)
Source: Atherosclerosis - August 1, 2023 Category: Cardiology Authors: J. M áchal, O. Hlinomaz, K. Kostolanská, O. Peš, Z. Šplíchal, A. Máchalová, J. Pokorný, Z. Moťovská, J. Juřica Source Type: research
Vonoprazan versus lansoprazole in erosive esophagitis — A systematic review and meta-analysis of randomized controlled trials
ConclusionBased on limited number of published non-inferiority RCTs, our analysis demonstrates that among patients with EE, vonoprazan 20 mg once-daily dosing achieves comparable and in those with severe EE, higher endoscopic healing rates as compared to lansoprazole 30 mg once-daily dosing. Both drugs have a comparable safety profile. (Source: Indian Journal of Gastroenterology)
Source: Indian Journal of Gastroenterology - July 7, 2023 Category: Gastroenterology Source Type: research
In vivo analysis of acute eletropharmacological effects of proton pump inhibitors using halothane-anesthetized dogs: a translational study of cardiovascular adverse events
J Toxicol Sci. 2023;48(7):375-385. doi: 10.2131/jts.48.375.ABSTRACTLong-term use of proton pump inhibitors (PPIs) is known to clinically induce hypomagnesemia, increasing the risk toward QT-interval prolongation and lethal ventricular arrhythmias, whereas PPIs can directly modulate cardiac ionic currents in the in vitro experiments. In order to fill the gap between those information, we assessed acute cardiohemodynamic and electrophysiological effects of sub- to supra-therapeutic doses (0.05, 0.5 and 5 mg/kg/10 min) of typical PPIs omeprazole, lansoprazole and rabeprazole, using halothane-anesthetized dogs (n = 6 for each ...
Source: Journal of Toxicological Sciences - July 2, 2023 Category: Toxicology Authors: Ryuichi Kambayashi Ai Goto Hiroko Izumi-Nakaseko Yoshinori Takei Atsushi Sugiyama Source Type: research
